ARCT Arcturus Therapeutics Holdings Inc
Company Analysis
Latest News
🔴 Arcturus Therapeutics is trading 5.6% down today amid possible reassessment of prior ARCT-810 data
Arcturus Therapeutics is trading at $13.34, down 5.56%, with no new company-specific announcement identified to explain the September 25 decline. - Investors...
🟢 Arcturus Therapeutics is trading 7.6% up today after ARCT-810 data and LUNAR 2.0 shift
Arcturus Therapeutics is trading 7.6% higher at $14.31 as investors assess interim ARCT-810 OTC-deficiency data and the transition to its LUNAR 2.0 delivery...
Arcturus Therapeutics Splits Wall Street, Following Platform Shift and Trial Data
BTIG maintained a Buy rating on Arcturus Therapeutics on Thursday. The firm lowered its price target to $20 from $23. This adjustment reflects the company’s...
Arcturus Packs Three Catalysts Into One Day — But Can a $400 Million Biotech Sustain the Momentum?
Shares of Arcturus Therapeutics surged 12.6% to $14.97, bucking a down market after the company stacked three announcements on September 23: positive mid-stage...
🟢 Arcturus Therapeutics is trading 12.6% up in pre-market after encouraging interim Phase 2 results for ARCT-810
Arcturus Therapeutics is trading 12.6% higher at $14.97 after its September 23, 2026, announcement of encouraging interim Phase 2 results for ARCT-810. - The...
Arcturus Announces Positive Phase 2 Data, New LUNAR 2.0 Platform, and myNEO Acquisition
Arcturus Therapeutics provided a significant corporate update, announcing encouraging interim Phase 2 clinical data for its OTC deficiency candidate ARCT-810,...
🟢 Arcturus Therapeutics is trading 6.68% up in after-hours trading on positive interim ARCT-810 Phase 2 results
Arcturus Therapeutics is trading 6.68% higher at $14.19 after reporting positive interim Phase 2 results for ARCT-810, its investigational mRNA therapy for OTC...
Arcturus Therapeutics Advances mRNA Drug, Normalizes Ammonia in Rare Disease Trial
Arcturus Therapeutics announced positive interim Phase 2 results for ARCT-810. This investigational mRNA therapy targets Ornithine Transcarbamylase (OTC)...
🔴 Arcturus Therapeutics is trading 5% down today amid broader market weakness
Arcturus Therapeutics is trading at $13.63, down 5.22%, amid weaker broader-market sentiment. - The Nasdaq Composite is down 0.78%, while the S&P 500 is down...
🔴 Arcturus Therapeutics is trading 5% down today after reversing recent gains
Arcturus Therapeutics is trading at $15.22, down -5.02%, after no clear company-specific negative announcement was identified for September 21, 2026. • The...
🔴 Arcturus Therapeutics is trading 5% down today as no clear company-specific catalyst was identified
Arcturus Therapeutics is trading 5.08% down at $16.07, with no clear company-specific negative announcement identified for September 18, 2026. - Shares...
🟢 Arcturus Therapeutics is trading 11.41% up today amid biotech-sector strength
Arcturus Therapeutics is trading 11.41% up now at $17.38, with the move primarily supported by biotechnology-sector strength; XBI is up 2.55%. - No new...
🟢 Arcturus Therapeutics is trading 5% up today as investors await late-September ARCT-810 Phase II readout
Arcturus Therapeutics is trading 5.02% up at $15.47, with investor attention focused on the expected late-September ARCT-810 Phase II readout and regulatory...
🟢 Arcturus Therapeutics is trading 5.79% up today after August CPI matched forecasts
Arcturus Therapeutics is trading 5.79% up at $14.79 as September 11, 2026 trading benefits from broad risk-on sentiment after August CPI matched forecasts. -...
🔴 Arcturus Therapeutics is trading 9.57% down today amid broader risk-off conditions
Arcturus Therapeutics is trading 9.57% down at $13.33 amid broader risk-off conditions. - The S&P 500 is down 0.56% and the Nasdaq Composite is down 0.79% as...
🔴 Arcturus Therapeutics is trading 5.2% down today — no clear company-specific catalyst identified
Arcturus Therapeutics is trading 5.2% down now at $14.82, with no clear company-specific catalyst identified for the September 9, 2026 decline. - Management...
🔴 Arcturus Therapeutics is trading 6.2% down today
Arcturus Therapeutics is trading 6.2% down now at $14.85, with no clear company-specific catalyst identified for the September 8, 2026 decline. - The company...
BlackRock buys 9.2% stake in Arcturus, targeting mRNA biotech growth
BlackRock Inc. disclosed a new investment in Arcturus Therapeutics Holdings Inc. via a recent SEC 13F filing. The asset management firm purchased more than 2.6...
🔴 Arcturus Therapeutics is trading 5% down today
Arcturus Therapeutics is trading at $15.88, down -5.16%, with no clear company-specific catalyst identified. - No September 3, 2026 announcement, earnings...
🟢 Arcturus Therapeutics is trading 10.3% up today with no clear catalyst identified
Arcturus Therapeutics is trading 10.3% up at $16.28, rebounding from its August 31, 2026 close of $14.76 with the immediate driver unclear. - The latest...